{"title":"派姆单抗联合lenvatinib治疗肾细胞癌伴横纹肌样特征的患者疗效显著：1例报告","authors":"Shinkuro Yamamoto , Satoshi Fukata , Takashi Karashima , Atsushi Kurabayashi , Rie Yoshimura , Kaoru Furihata , Yuhei Shiba , Tomoya Nao , Hirofumi Satake , Keiji Inoue","doi":"10.1016/j.eucr.2025.103140","DOIUrl":null,"url":null,"abstract":"<div><div>Renal cell carcinoma (RCC) with rhabdoid features is a rare and highly aggressive condition with no established treatment for early recurrence. We herein report a case involving a 58-year-old man who underwent nephrectomy for clear-cell RCC with rhabdoid features and developed rapid metastases within 3 months. Treatment with pembrolizumab plus lenvatinib achieved a sustained partial response, except for vertebral metastasis. Thereafter, radiotherapy was added, and systemic therapy resumed, which maintained disease control for 2 years. Immunohistochemistry revealed partial PD-L1 expression in rhabdoid areas. This case highlights the potential efficacy of pembrolizumab plus lenvatinib in RCC with rhabdoid features.</div></div>","PeriodicalId":38188,"journal":{"name":"Urology Case Reports","volume":"62 ","pages":"Article 103140"},"PeriodicalIF":0.4000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Robust response to pembrolizumab plus lenvatinib in a patient with renal cell carcinoma with rhabdoid features: A case report\",\"authors\":\"Shinkuro Yamamoto , Satoshi Fukata , Takashi Karashima , Atsushi Kurabayashi , Rie Yoshimura , Kaoru Furihata , Yuhei Shiba , Tomoya Nao , Hirofumi Satake , Keiji Inoue\",\"doi\":\"10.1016/j.eucr.2025.103140\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Renal cell carcinoma (RCC) with rhabdoid features is a rare and highly aggressive condition with no established treatment for early recurrence. We herein report a case involving a 58-year-old man who underwent nephrectomy for clear-cell RCC with rhabdoid features and developed rapid metastases within 3 months. Treatment with pembrolizumab plus lenvatinib achieved a sustained partial response, except for vertebral metastasis. Thereafter, radiotherapy was added, and systemic therapy resumed, which maintained disease control for 2 years. Immunohistochemistry revealed partial PD-L1 expression in rhabdoid areas. This case highlights the potential efficacy of pembrolizumab plus lenvatinib in RCC with rhabdoid features.</div></div>\",\"PeriodicalId\":38188,\"journal\":{\"name\":\"Urology Case Reports\",\"volume\":\"62 \",\"pages\":\"Article 103140\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2214442025002116\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214442025002116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Robust response to pembrolizumab plus lenvatinib in a patient with renal cell carcinoma with rhabdoid features: A case report
Renal cell carcinoma (RCC) with rhabdoid features is a rare and highly aggressive condition with no established treatment for early recurrence. We herein report a case involving a 58-year-old man who underwent nephrectomy for clear-cell RCC with rhabdoid features and developed rapid metastases within 3 months. Treatment with pembrolizumab plus lenvatinib achieved a sustained partial response, except for vertebral metastasis. Thereafter, radiotherapy was added, and systemic therapy resumed, which maintained disease control for 2 years. Immunohistochemistry revealed partial PD-L1 expression in rhabdoid areas. This case highlights the potential efficacy of pembrolizumab plus lenvatinib in RCC with rhabdoid features.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
